Miniaturising insulin pumps
Next-generation type 1 diabetes technology such as wearable devices and implants are critical future developments for people with the condition to keep healthy. Miniaturising devices such as insulin pumps will make them less intrusive, heavy and cumbersome, breaking down barriers to their use.
(Image removed) Cambridge-based biopharmaceutical firm Arecor Ltd announces today it will collaborate with JDRF on a project which will see a focus on perfecting a concentrated form of insulin. This would mean that a smaller vial is needed to hold the liquid in an insulin pump, allowing the whole pump to miniaturise.Currently, concentrated insulin is too slow-acting when placed in the human body. But Arecor Ltd will work to perfect a concentrated insulin that acts at the same speed as currently available rapid-acting insulins for people with type 1 diabetes. It is hoped the dosing volume could be reduced five to 10-fold.
Image: A current insulin pump.
About Arecor Ltd
Arecor Ltd is based at the world-renowned Cambridge Science Park. The firm focuses on adapting proteins such as insulin. The new partnership will see Arecor Ltd and JDRF working closely together and JDRF will provide up to £680,000 over 12 months.
For more info visit our website.
__________________________________________